At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

Engaged Capital exited its stakes in BlackLine (NASDAQ:BL) and Nevro (NYSE:NVRO) and took a new position in Chart Industries ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Highlights,Several firms have recently revised their price targets for Ingredion.,Stephens lowered its target price for the ...

Highlights,Increased institutional ownership in Vertex Inc. with notable transactions recorded.,Strong year-over-year revenue ...

Healthcare sector shows strong performance in January amid signs of a brighter 2025, according to analysts. Read more here.

Vertex Pharmaceuticals, Inc. shares are currently trading up about 6.2% on the day. The chart below shows the one year performance of VRTX shares, versus its 200 day moving average: ...